A Combination Proof-of-Concept Phase 2 Clinical Trial of AB-729 in Combination with AB-506 in Subjects with Chronic Hepatitis B
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs AB-506 (Primary) ; AB-729 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Proof of concept
- Sponsors Arbutus Biopharma
- 03 Oct 2019 According to an Arbutus Biopharma media release, the company announced to discontinue the clinical development of AB-506 due to two cases of acute hepatitis in phase 1a portion of the trial ACTRN12618000987268.
- 03 Oct 2019 Status changed from planning to withdrawn prior to enrolment, according to an Arbutus Biopharma media release.
- 05 Aug 2019 According to an Arbutus Biopharma media release, the company anticipate moving into this combination proof-of-concept phase 2 clinical trial in subjects with chronic hepatitis B in the second half of 2020.